Shanghai Allink Biotherapeutics Co., Ltd.

This study tests a new drug called ALK201 in people with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety and find the best dose. About 202 adults will take part in this early-phase trial.